Abstract:One of the most feared complications in medicine is sudden death caused by drug-induced proarrhythmia. Accordingly, concerted efforts have been made to define a drug’s proarrhythmic potential before regulatory approval. Monitoring for QT prolongation is one such method. Patients with heart failure represent a particularly high-risk population for torsade de pointes because of structural and electric remodeling that impair repolarization reserve. However, these patients are frequently excluded from clinical trials. Preclinical models simulate some of the electric remodeling of heart failure and form an important part of safety evaluations during early drug development. Clinical programs usually include a thorough QT study, which attempts to find a small mean change in QTc that serves as a surrogate for the risk of torsade de pointes. The impairment of repolarization reserve in heart failure goes beyond QT prolongation, however, and other clinical methods of measuring this propensity may be necessary to obtain a complete picture of a drug’s arrhythmic potential. Heart failure (HF) is a common and serious affliction. HF is a listed diagnosis in as many as 65% to 70% of hospital admissions each year in the United States.1 The prevalence of this disease continues to increase because of to a rise in coronary artery disease and diabetes incidence, an increase in the age of the population, and a reduction in the probability of sudden cardiac death (SCD) in HF with aggressive use of implantable cardioverter-defibrillators. The net result is a larger population of patients living longer with more comorbidities, and, as a corollary, more polypharmacy. HF has been recognized as one of several clinical risk factors for druginduced proarrythmia.2,3 Many classes of drugs have been shown to improve all-cause mortality in HF and have revolutionized both the treatment and prognosis of this condition. Although there is a need for continued development of drug treatments for HF, we must ensure that these treatments do not increase the risk for life-threatening arrhythmias. Assessing this risk accurately, however, has proven challenging. Although antiarrhythmic drugs are understood to have proarrhythmic potential, it has only recently been understood that noncardiac drugs also carry such risk. The withdrawal of terfenadine (Seldane) from the market in 1998 due to several cases of torsade de pointes (TdP) markedly heightened awareness that such drugs can be cardiotoxic. Since then, numerous noncardiac drugs have been withdrawn from the market because of a TdP risk, including prenylamine, cisapride, and sparfloxacin. In a large sample of patients treated between 1995 and 2003, the use of QT-prolonging drugs in the general population was associated with a significantly increased risk of SCD.4 In patients with coronary artery disease, the use of QTprolonging drugs confers a higher risk of SCD, especially in patients with diabetes mellitus.5 This has led to increased oversight by regulatory bodies. Concern about proarrhythmia has become the most common reason for drug nonapproval since the turn of the century.6 The most important predictor of TdP is QT interval prolongation, and therefore TdP and drug-induced QT prolongation have become virtually synonymous. There appear to be 3 components that are necessary for the genesis of TdP: lengthening of the cardiac action potential duration (APD), early afterdepolarizations (EAD), and transmural dispersion of repolarization allowing for propagation of the EAD and reentry.7 Clinical risk factors for TdP, as described by Roden, include HF, which, in many ways, is an excellent example of how 1 or more of these requisite conditions can be met.2 This article will discuss the cellular basis for repolarization abnormalities in HF, the preclinical assessment of TdP risk including in vitro and in vivo models, clinical assessments including the thorough QT study, ideas for refinement of the process, and finally, examples of emerging HF treatments and how their liabilities are being assessed.

Drug-induced proarrhythmia: Discussion and considerations for clinical practice

Drug‐induced torsades de pointes and implications for drug development

Development of Therapeutics for Heart Failure

Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort

Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management

An Updated Safety Review of the Relationship Between Atypical Antipsychotic Drugs, the QTc Interval and Torsades de Pointe As: Implications for Clinical Use

Drug-induced QT interval prolongation and torsades de pointes

Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes

Prevention of Torsade de Pointes in Hospital Settings

Exploring the hidden danger of noncardiac drugs.

Drug-induced long QT syndrome: Concept and non-clinical models for predicting the onset of drug-induced torsade de pointes in patients in compliance with ICH E14/S7B guidance

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system

Proarrhythmic Potential of Low-risk Drugs That Affect the Ventricular Repolarization

Long QT Syndrome With Drugs Used in the Management of Arrhythmias: A Systematic Review

QT Prolongation Preceding Ventricular Fibrillation After Amiodarone Administration: A Case Report

Discarding the Baby with the Bathwater

Torsade de pointes: mechanisms and management

QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes"

QTc Prolongation and Torsades De Pointes Due to a Coadministration of Fluoxetine and Amiodarone in a Patient with Implantable Cardioverter-Defibrillator Case Report and Review of the Literature

Diagnosis and Treatment of Drug Induced Acquired Long QT Syndrome

Assessment of Drug-Induced Proarrhythmia: the Importance of Study Design in the Rabbit Left Ventricular Wedge Model.